Key points
Introduction
Umbilical cord blood (UCB) is increasingly used as an alternative donor stem cell source for treating patients with leukemia, inborn errors of metabolism, immune deficiencies and bone marrow failure syndromes. The use of UCB donors has important advantages, such as: (1) prompt availability (HLA-typed and banked);
(2) less stringent HLA-matching criteria, with a donor being available for >95% of the patients 1 ; (3) lower probability of graft-versus-host disease (GvHD), while maintaining a powerful graft-versus-leukemia (GvL) effect [2] [3] [4] . However the use of UCB, is also associated with a prolonged neutropenic period and higher rates of graft failure particularly for UCB units with low cell numbers (<3x10e7 total nucleated cells/kg). Moreover, compared to matched sibling and matched unrelated donor (MUD) hematopoietic cell transplantation (HCT), patients undergoing UCBT experience a delayed T-cell reconstitution, with an increased risk of opportunistic infections during the first three months post transplant [5] [6] [7] . This is a significant concern in patients with ongoing bacterial/fungal infection at the time of transplantation and/or in patients with a history of multiple viral reactivations.
One explanation for the delayed T-cell reconstitution in UCBT recipients may be the use of in vivo T-cell depletion (thymoglobulin or alemtuzumab) in the conditioning regimen. Thymoglobulin (ATG) doses of 10mg/kg are usually given in the UCBT setting where, on average, a log less T-cells are infused compared to a bone marrow donor graft. Importantly, in some pharmacokinetic studies Thymoglobulin can be detected in the recipient's plasma up to 25-60 days after HCT 8, 9 . In recent years, some transplant centers have started to omit ATG in the cord blood setting 10 . Comparative analyses have however not been published previously. In line with our hypothesis, our group (Chiesa et al. 11 ) recently reported that in the absence of ATG, using Cyclosporin A and MMF as GVHDprophylaxis, an excellent immune recovery can be observed following unrelated UCBT. From these data can be concluded that the intrinsic immune recovery after UCBT in children can be very rapid, and that early T-cell reconstitution in For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From this context is thymus-independent and driven by the peripheral expansion of naïve cord blood lymphocytes infused with the graft. Moreover, it was observed that UCB naïve T-lymphocytes appear to undergo a rapid conversion to a memory/effector phenotype in response to viral/antigenic stimuli within the first 2 months post transplant 12, 13 and that a long term diverse immune repertoire is achieved 14 . Nevertheless, a drawback of omitting ATG prior to UCBT may be an increased incidence of GvHD or graft rejection which may negatively impact on survival.
For the first time we report the role and timing of ATG on immune reconstitution and clinical outcome in children undergoing unrelated UCBT. Despite the heterogeneity of this population, these data may provide better guidance to future decisions on the use of ATG (or other serotherapy) in UCBT protocols.
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Methods

Setting and study population
All patients who received an unrelated UCBT at either the University Medical Center (UMC) Utrecht or at Great Ormond Street Hospital (GOSH), London were included in this study. Patients were divided in 3 groups: those who received ATG late (between day -5 to 0) in the conditioning regimen, those who received ATG early (between day -9 to -5), and those who received no ATG. hemophagocytic lymphohistiocytosis who received a double dose and patients with a CD3+ T-cell count <300x10e6/L (before conditioning) who received a dose reduced by 50%. All immune reconstitution data were collected prospectively when patients were enrolled for HCT after written informed consent was obtained in accordance with the Declaration of Helsinki and institutional ethical committee approval for sample and data collection.
Transplantation details, conditioning and supportive care.
Patients' and transplant's characteristics are summarized in Table 1 . Children were conditioned with either a myeloablative or a reduced intensity conditioning 
Donor selection and processing of the graft
Umbilical cord blood (UCB) units were obtained from (inter-)national cord blood banks. UCB units were required to be HLA matched to the patient at 4/6 or greater for HLA A-, HLA-B-and HLA-DRB1-antigens (HLA-A, -B serological typing and HLA-DRB1 high resolution allele typing). The minimum total nucleated cell (TNC) dose required for the transplant was 2.5, 3 and 5x10e7 NC/kg in case of a 6/6, 5/6 or 4/6 HLA-matched UCB-unit, respectively. Children who did not meet these criteria received a double UCBT: both CB units were required to be a 4/6 match with each other and the patient and having a minimal cumulative cell dose of 4x10e7 NC/kg.
In GOSH, prior to transplantation, full allelic typing of HLA A, B, C, DRB1 and DQB1 antigens was performed on the cord sample and from April 2010 units with more than three allelic mismatches were not selected.
Post UCBT follow-up
Engraftment and chimerism: myeloid recovery was defined as the first of three consecutive days with an absolute neutrophil count exceeding 0.5x10e9/L, while Remission status: in GOSH bone marrow studies were standard post engraftment. In the UMC Utrecht these were not routinely performed, only in case of poor engraftment or evidence of disease relapse in the peripheral blood.
Relapse was based on hematological, immunological and pathological confirmation of disease recurrence.
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Toxicity was scored according to National Cancer Institute Toxicity Criteria. The diagnosis of aGvHD was made clinically, and confirmed pathologically with skin, mucosal or liver biopsy whenever possible. Grading of aGvHD was performed according to the Seattle criteria with the caveat of late aGVHD to occur after day 100, as described by the NIH consensus guidelines 15, 16 . Chronic GVHD was defined according to NIH guidelines. 
Statistical analyses
The data were retrospectively analyzed. Differences in patients' characteristics and in immune reconstitution parameters were assessed using Kruskal-Wallis tests for continuous data and Univariate predictors of outcome that were statistically significant (P-value≤0.10)
were selected for multivariate Cox proportional hazards models. Results are expressed as hazard ratios (HR) and their corresponding 95% confidence intervals (95%CI).
For analyses of dichotomous outcome parameters the univariate and multivariate logistic regression analyses were used. Dichotomous outcomes (e.g., viral reactivation: yes/no) were used as dependent variables and predictors as independent variables. Univariate predictors of outcome that were statistically significant (P-value≤0.10), were selected for multivariate logistic regression analysis. Results are expressed as odds ratios (OR) and their corresponding 95%CI. CIs not including 1 (P-value≤0.05) were considered statistically significant. Statistical analysis was performed using SPSS version 19.0.
For
Results
Patients, donors and transplant characteristics
A total of 127 patients were included; 48 in the late ATG group, 33 in the early ATG group and 46 in the no ATG group (Table 1) . No difference in ATG dose was found between the two ATG groups. RIC regimes were more common in the no ATG group.
Indication for UCBT was different amongst the treatment groups: there was a larger proportion of children with primary immunodeficiencies in the no ATG group, while there was a higher proportion of metabolic diseases in the late ATG and early ATG groups (Table 1) . This difference resulted in a lower median age at transplantation (p=0.006) and a higher UCB-CD34+/kg cell dose in the no ATG group (Table 1) . Although cord blood selection rules differ between the two centers, HLA-disparity ended up not being different between centers (p=0.49).
Engraftment and survival
The CI for neutrophil engraftment within 60 days post-UCBT was 95%±4% for the no ATG group, 97%±3% for the early ATG and 90%±4% for the late ATG group. A more rapid myeloid and platelet recovery was observed in the early ATG group (Table 1, Fig.1B : the median time to neutrophil recovery was 21 days in the no ATG, as opposed to 17 days in the early ATG (p = 0.01) and 21 days (NS) in the late ATG group. Non-engraftment rates were low, with no statistically significant difference amongst the 3 groups (no ATG= 4%, early ATG= 3% and late ATG= 10%; p=NS). Equally, secondary graft failure rates were not statistically different: 2%, 3% and 11% respectively.
The 3-year estimated probability of overall survival was similar in the three groups (no ATG= 71%±8%, early ATG= 68%±9% and late ATG= 61%±7%). Nonrelapse mortality, relapse rate and event-free survival were also not significantly different. The 3-year estimate probability of event-free survival was 61%±8% for the no ATG group, 68%±8% for the early ATG group and 55%±7% for the late ATG group (Fig. 1A) .
In multivariate analysis only the use of a mismatched 4/6 or 5/6 UCB unit (HR 4.2, 95% CI 1.1-15.8, p=0.033) was found to be a predictor for lower EFS. The use of ATG was not. For NRM none of the variables were found to be significant predictors.
Immune reconstitution
Immune reconstitution data are available for 85-88% of the timepoints 1,2,3,6 and 12 months post UCBT. Using multivariate analysis the only predictor for early immune-reconstitution after UCBT was the omission of ATG from conditioning regimen (No ATG: OR 57 with a 95% CI 12-256, p<0.001). We found that CD3+, CD4+ and CD4+ naïve T-cell numbers were a log higher in the no ATG group compared to the early ATG and late ATG groups at 1,2,3,6 and 12 months post-UCBT (p<0.001, Fig. 2B ). The median CD3+ T-cell count in the no ATG group at 1,2,3,6 and 12 months post UCBT was 340x10e6/L, 720x10e6/L, 535x10e6/L, 940x10e6/L, and 1860x10e6/L respectively (Fig. 2B) .
Interestingly, patients in the early ATG group had significantly higher CD3+, CD4+ and CD4+ naïve T-cell counts at 1 and 2 months post-UCBT, when compared to patients in the late ATG group (1 month: p=0.02, 2 months: P=0.036, 3 months p=0.13, Fig. 2 ). There was no difference in NK-and B-cell recovery amongst the 3 groups: normal NK cell numbers were observed in all groups 1 month post UCBT and normal B-cells were observed 2 months post UCBT ( Fig.2A) 
Transplant-related complications
Viral reactivations: the no ATG group showed a lower number of episodes of viral reactivations (p=0.021) compared to patients who received ATG (Fig.3) , while no difference was observed between the early ATG and late ATG groups. There was also a lower number of deaths from viral infections (p=0.002) in the group with no ATG compared to the groups that received ATG. Specifically for EBV: preemptive rituximab therapy in a dose of 375 mg/m2 was administered to 10
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From patients (2 in the no ATG group, 2 in the early ATG group and 6 in the late ATG group). However, clinically apparent post-transplant lymphoproliferative disorder was diagnosed only in 1 additional patient, who recovered after treatment and has good immune reconstitution and quality of life. Four of the 11 patients treated for EBV died. Neither of them died directly of EBV-infection. One died of aGVHD, another of invasive fungal infection and two of toxicity-related multi-organ failure and GVHD. All four were in the late ATG group.
The number of patients with opportunistic (including fungal) infections was not different for the three groups (p=0.24).
GvHD and non-infectious lung-injury
With multivariate analysis, both no ATG (HR 8.2, 95% CI 3.2-22.0, p<0.001) and early ATG (OR 3.9 95%CI 1.5-10.5, p=0.005) were independent predictors for aGVHD as opposed to the late ATG group.
A higher incidence of grade II-IV (p=0.003) and grade IlI-IV aGVHD (p=0.018) was observed in the no ATG group (Fig.1C) compared to the early ATG group.
Patients in the early ATG group experienced a significantly higher incidence of grade II-IV aGVHD compared to patients in the late ATG group (44% vs. 14%, p=0.009). However, no difference was found for grade III-IV aGVHD (18% vs 5%, p=0.15) between the 2 ATG groups (data not shown). Despite the higher rate of aGVHD in the no ATG and early ATG groups, the incidence of cGVHD was not statistically different amongst the 3 groups: 12%±6% in the no ATG group, 11%±6% in the early ATG group and 28%±8% in the late ATG group (Fig. 1D) .
The lowest incidence of non-infectious lung injury was found to be in the early ATG group (17±7%), but this was not significantly different to the other 2 groups (no ATG group: 37%±15% p=0.42, late ATG-group: 27%±7% (p=0.19); (data not shown).
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Discussion
In this study we demonstrate that the use of in vivo T-cell depletion prior to UCBT significantly affects the early and late post-transplant T-cell reconstitution. It cannot be ruled out that differences between the HCT platforms in the two centers (e.g. GVHD-prophylaxis and conditioning regimen) contributed to the better immune reconstitution and higher GVHD rate observed in the no-ATG group. However, the hypothesis that ATG is important, is supported by the finding, that early rather than late administration of ATG also facilitated a better T-cell recovery within the first 2 months post UCBT using the same transplant platform. Furthermore, a similar observation has also been done for double UCBT without ATG by Sauter et al., showing a steady immune recovery, a low infection related mortality after day 120, but a higher GVHD risk compared to patients that received ATG prior to double UCBT 10 .
In this manuscript we show that children transplanted without ATG as part of their conditioning regimen, experienced a remarkably quick CD3+ cell recovery early after UCBT, with a median T-cell-count of 720x10e6/L only two months after transplant. This is in contrast to those patients treated with early or late ATG, where a median CD3+ T-cell-count of <100x10e6/L was achieved at the same time point. The lymphocyte recovery was CD4+ biased as previously described 9, 17 , and the reason for this is currently unknown. Similarly, other studies have shown a comparable pattern of poor early T-cell recovery after UCBT, in the context of in vivo T-cell depletion 1, 6, [17] [18] [19] .
The improved immune reconstitution in the group not receiving ATG prior to transplantation was associated with a lower incidence of reactivation of EBV, CMV and/or Adenovirus. Various reports have shown that UCBT-recipients are at increased risk of viral reactivation due to the delayed immune recovery [2] [3] [4] [20] [21] [22] , and early initiation of pre-emptive antiviral therapy is frequently used to prevent viral disease, using a lower cut-off qDNA-value in CB-recipients 5, 6, 23, 24 . Although we did not find the MAC/RIC regimen to be a predictor in this cohort; ATG used in association with RIC regimens has been shown to further increase the risk of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From viral reactivation and specifically also the risk of EBV PTLD 25, 26 . Overall, EBV PTLD was well manageable in this cohort with preemptive treatment. Only one patient developed PTLD and she recovered completely.
The observed reduced incidence of viral reactivations in the no ATG group is likely the result of not depleting the UCB-graft of lymphocytes, which although naïve, have the capacity of rapidly differentiating into the effector/memory phenotype in response to antigen stimulation even early after UCBT 8, 9, 11, 27 . It could be speculated that an early specific immune reconstitution post-UCBT may also lead to a more powerful graft-versus leukemia effect, as suggested in other studies 2, 11, [28] [29] [30] . The number of patients with malignant disease in each group in this study was too small and disease-type and conditioning too heterogeneous to assess this.
In our pediatric population of children with mixed malignant and non-malignant indications, ATG was not required for engraftment as the CI of neutrophil engraftment at day 60 was similar between groups (Fig.1B) . In contrast with others we found HLA disparity to be a predictor for EFS but not cell dose. This can be explained by the strict "cell dose rules" that were applied and the low median weight of the studied cohort leading to a high median cell dose in this study of 7,3 (0.8-33.2) x10e7 NC/kg after thawing.
The clinical benefit of an early immune reconstitution in the no ATG group has to be balanced against the higher incidence of moderate to severe aGvHD observed in this cohort. Interestingly, this was not associated with a higher incidence of chronic GvHD or non-relapse mortality. Historically UCBT has been associated with a lower incidence of aGvHD compared to MUD HCT, as shown in various comparison studies. This study puts that in perspective, showing that the incidence of aGvHD in UCBT is very much influenced by in vivo T-celldepletion. Rates of aGvHD reported in this study are higher than previously published by other authors: e.g. Verneris et al reported aGvHD (grade ll-lV) rates of 29% for single UCBT and 48% for double UCB transplants 12, 13, 31 . A more recent and large Eurocord study showed similar GVHD incidences in single and double UCBT 15, 16, 32 . MacMillan reported that the omission of ATG prior to double
UCBT did not influence mortality and led mainly to an increased incidence of grade II skin GvHD 10, 33 . The aGvHD rates in our cohort may however also be influenced by the selection of primary immunodeficiency patients in the no ATG group. Such children may be more at risk for aGvHD due to ongoing infections and tissue inflammation, Importantly however, a higher rate of aGvHD did not lead to a higher incidence of cGvHD, viral reactivations, or higher NRM.
In the most commonly used UCBT-protocols, particularly with "late" 
